Antimicrobial and antimycotic therapy of intra-abdominal infections;Antibiotika- und Pilztherapie bei Intraabdominellen Infektionen

Chirurg

Volumn 79, Issue 4, 2008, Pages 295-305

  Kujath, P ^a,c   Hoffmann, M ^a   Rodloff, A ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antibiotic therapy; De escalation; Evidence based; Guidelines; Peritonitis

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL INFECTION; CHRONIC DISEASE; CROSS INFECTION; EARLY DIAGNOSIS; HUMAN; MULTIDRUG RESISTANCE; MYCOSIS; PERITONITIS; SURGICAL INFECTION;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CHRONIC DISEASE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EARLY DIAGNOSIS; HUMANS; MYCOSES; PERITONITIS; SURGICAL WOUND INFECTION;

EID: 42449157076     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00104-008-1484-z     Document Type: Article

References (66)

1. Allo MD, Bennion RS, Kathir K et al. (1999) Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 65: 99-104
2. Andäker L, Höjer H, Kihlström E et al. (1987) Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 153: 185-192
3. Angeras MH, Darle N, Hamnström K et al. (1996) A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 28: 513-518
4. Babinchak T, Ellis-Grosse E, Dartois N et al. (2005) The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis [Suppl 5] 41: S354-S367
5. Barie PS, Vogel SB, Dellinger EP et al. for the Cefepime Intra-abdominal Infection Study Group (1997) A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 132: 1294-1302
6. Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13: 195-199
7. Bozorgzadeh A, Pizzi WF, Barie PS et al. (1999) The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 177: 125-131
8. Brismar B, Malmborg AS, Tunevall G et al. (1995) Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 35: 139-148
9. Burnett RJ, Haverstock DC, Dellinger EP et al. (1995) Definition of the role of enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 118: 716-723
10. Calandra T, Bille J, Schneider R et al. (1989) Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 2: 1437-1440
11. Cohn SM, Lipsett PA, Buchman PG et al. (2000) Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 232: 254-262
12. Dougherty SH, Sirinek KR, Schauer PR et al. (1995) Ticarcillin/ clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 61: 297-303
13. Dupont H, Bourichon A, Paugam-Burtz C et al. (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31: 752-757
14. Eagye KJ, Kuti JL, Nicolau DP (2007) Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling. Surg Infect 8: 215-226
15. Eklund AE, Nord CE (1993) A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother [Suppl A] 31: 79-85
16. Evans HL, Raymond DP, Pelletier SJ et al. (2001) Tertiary peritonitis (recurrent diffuse or localized peritonitis) is not an independent predictor of mortality in surgical patients with intraabdominal infection. Surg Infect 2: 255-263
17. Fabian TC, Croce MA, Payne LW et al. (1992) Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery 112: 788-795
18. Hopkins JA, Wilson SE, Bobey DG (1994) Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy. World J Surg 18: 933-938
19. Huizinga WK, Warren BL, Baker LW et al. (1995) Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother [Suppl A] 36: 179-189
20. Jaccard C, Troillet N, Harbarth S et al. (1998) Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 42: 2966-2972
21. Kirton OC, O'Neill PA, Kestner M et al. (2000) Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, doubleblind, placebo-control trial of 24 hours versus 5 days. J Trauma 49: 822-832
22. Krepel CJ, Gohr C, Edmiston CE, Condon RE (1995) Surgical sepsis: constancy of antibiotic susceptibility of causativ organismns. Surgery 117: 505-509
23. Kujath P (2002) Peritonitis. Uni-Med, Bremen
24. Lau WK, Mercer D, Itani KM et al. (2006) Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50: 3556-3561
25. Lennard ES, Minshew BH, Dellinger EP, Wertz M (1980) Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 115: 918-921
26. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH (1982) Implications of leukocytosis and fever at conclusion of antibiotic therapy for intraabdominal sepsis. Ann Surg 195: 19-24
27. Luke M, Iversen S, Sondergaard J et al. (1991) Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 157: 397-401
28. Marangoni M, Song J, Herrington J et al. (2006) Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 244(2): 204-211
29. Marshall JC, Christou NV, Horn R, Meakins JL (1988) The microbiology of multiple organ failure. Arch Surg 123: 309-315
30. Mazuski JE, Sawyer RG, Nathens AB et al. (2002) The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 3: 175-233
31. McGowan JE Jr, Gerding DN (1996) Does antibiotic restriction prevent resistance? New Horiz 4: 370-376
32. Montravers P, Gauzit R, Muller C et al. (1996) Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 23: 486-494
33. Montravers P, Dupont H, Gauzit R et al. (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34: 646-652
34. Nathens AB, Rotstein OD, Marshall JC (1998) Tertiary peritonitis: clinical features of a complex nosocomial infection. World J Surg 22: 158-163
35. Nathens AB, Cook CH, Machiedo G et al. (2006) Defining the research agenda for surgical infection: a consensus of experts using the Delphi approach. Surg Infect 7: 101-110
36. Nguyen MH, Yu VL, Morris AJ et al. (2000) Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30: 870-876
37. Ohlin B, Cederberg A, Forssell H et al. (1999) Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 165: 875-884
38. Paul M, Silbiger I, Grozinsky S et al. (2006) Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 1: CD003344
39. Peoples JB (1986) Candida and perforated peptic ulcers. Surgery 100: 758-764
40. Pieracci FM, Barie PS (2007) Intra-abdominal Infections. Curr Opin Crit Care 13: 440-449
41. Rex JH (2006) Candida in the peritoneum: passenger or pathogen? Crit Care Med 34: 902-903
42. Roehrborn A, Thomas L, Potreck O et al. (2001) The microbiology of postoperative peritonitis. Clin Infect Dis 33: 1513-1519
43. Rossi F, Baquero F, Hsueh PR et al. (2006) In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 58: 205-210
44. Rotstein OD, Meakins JL (1990) Diagnostic and therapeutic challenges of intraabdominal infections. World J Surg 14: 159-166
45. Schein M, Assalia A, Bachus H (1994) Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg 81: 989-991
46. Seguin P, Laviolle B, Chanavaz C et al. (2006) Factors associated with multidrugresistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 12: 980-985
47. Shlaes DM, Gerding DN, John JF Jr et al. (1997) Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 25: 584-599
48. Sitges-Serra A, Lopez M, Girvent M et al. (2002) Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 89: 361-367
49. Snydman DR, Cuchural GJ Jr, McDermott L, Gill M (1992) Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 36: 540-544
50. Solomkin JS, Flohr AB, Quie PG, Simmons RL (1980) The role of Candida in intraperitoneal infections. Surgery 88: 524-530
51. Solomkin JS, Mazuski JE, Baron EJ et al. (2003) Guidelines for the selection of antiinfective agents for complicated intra-abdominal infections. Clin Infect Dis 37: 997-1005
52. Solomkin JS, Reinhart HH, Dellinger EP et al. (1996) Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223: 303-315
53. Solomkin JS, Yellin AE, Rotstein OD et al. (2003) Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237: 235-245
54. Trede M, Linder MM, Welsch G (1980) Die Indikation zur Relaparotomie bei postoperativer Peritonitis. Langenbecks Arch Chir 352: 295
55. Vogel F, Bodmann KF und die Expertenkommision der Paul-Ehrlich- Gesellschaft (2004) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemother J 13: 46-105
56. Walker AP, Nichols RL, Wilson RF et al. (1993) Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217: 115-121
57. Wittmann DH, Schein M (1996) Let us shorten antibiotic prophylaxis and therapy in surgery. Am J Surg 172: 26S-32S
58. Wong PF, Gilliam AD, Kumar S et al. (2005) Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev 2: CD004539
59. Yellin AE, Heseltine PN, Berne TV et al. (1985) The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 161: 303-307
60. Basoli A, Meli EZ, Mazzocchi P et al. (1997) Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 29(5): 503-508
61. Condon RE, Walker AP, Sirinek KR et al. (1995) Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 21:544-550
62. Namias N, Solomkin JS, Jensen EH et al. (2007) Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 8(1): 15-28
63. Poenaru D, de Santis M, Christou NV (1990) Imipenem versus tobramycin - antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 33: 415-422
64. Mehtar S, Dewar EP, Leaper DJ et al. (1997) A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infection. J Antimicrob Chemother 39: 631-638
65. Kumar A, Roberts D, Wood KE et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589-1596
66. Niederman MS (2006) Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 42 [Suppl 2]: 72-81